Skip to main content

Correcting Genetic Spelling Errors

Correcting Genetic Spelling Errors With Next-Generation Crispr


Sam Berns was my friend. With the wisdom of a sage, he inspired me and many others about how to make the most of life. Afflicted with the rare disease called progeria, his body aged at a rapid rate, and he died of heart failure at just 17, a brave life cut much too short.

My lab discovered the genetic cause of Sam’s illness two decades ago: Just one DNA letter gone awry, a T that should have been a C in a critical gene called lamin A. The same misspelling is found in almost all of the 200 individuals around the world with progeria.

The opportunity to address this illness by directly fixing the misspelling in the relevant body tissues was just science fiction a few years ago. Then Crispr came along—the elegant enzymatic apparatus that allows delivery of DNA scissors to a specific target in the genome. In December 2023, the FDA approved the first Crispr-based therapy for sickle cell disease. That approach required taking bone marrow cells out of the body, making a disabling cut in a particular gene that regulates fetal hemoglobin, treating the patient with chemotherapy to make room in the marrow, and then reinfusing the edited cells. A relief from lifelong anemia and excruciating attacks of pain is now being delivered to sickle cell patients, albeit at very high cost.

For progeria and thousands of other genetic diseases, there are two reasons why this same approach won’t work. First, the desired edit for most misspellings will not usually be achieved by a disabling cut in the gene. Instead, a correction is needed. In the case of progeria, the disease-causing T needs to be edited back to a C. By analogy with a word processor, what’s needed is not “find and delete” (first-generation Crispr), it’s “find and replace” (next-generation Crispr). Second, the misspelling needs to be repaired in the parts of the body that are most harmed by the disease. While bone marrow cells, immune cells, and skin cells can be taken out of the body to administer gene therapy, that won’t work when the main problem is in the cardiovascular system (as in progeria) or the brain (as in many rare genetic diseases). In the lingo of the gene therapist, we need in vivo options.

The exciting news in 2025 is that both of these barriers are starting to come down. The next generation of Crispr-based gene editors, pioneered particularly elegantly by David Liu of the Broad Institute, allows precise corrective editing of virtually any gene misspelling, without inducing a scissors cut. As for delivery systems, the family of adeno-associated virus (AAV) vectors already provides the ability to achieve in vivo editing in eye, liver, and muscle, though there is still much work to be done to optimize delivery to other tissues and ensure safety. Nonviral delivery systems such as lipid nanoparticles are under intense development and may displace viral vectors in a few years.

Working with David Liu, Sam Berns’ mom, and Leslie Gordon of the Progeria Research Foundation, my research group has already shown that a single intravenous infusion of an in vivo gene editor can dramatically extend the life of mice that have been engineered to carry the human progeria mutation. Our team is now working to bring this forward to a human clinical trial. We are truly excited about the potential for kids with progeria, but that excitement could have even greater impact. This strategy, if successful, could be a model for the approximately 7,000 genetic diseases where the specific misspelling that causes the disease is known, but no therapy exists.

There are many hurdles, cost being a major one as private investment is absent for diseases that affect only a few hundred individuals. However, success for a few rare diseases, supported by government and philanthropic funds, will likely lead to efficiencies and economies that will help with other future applications. This is the best hope for the tens of millions of children and adults who are waiting for a cure. The rare-disease community must press on. That’s what Sam Berns would have wanted.

Gene expression, Genetic variation, DNA sequencing, Gene therapy, Genomic editing, CRISPR-Cas9, Genetic disorders, Population genetics, Hereditary traits, Epigenetics, Genome-wide association study, Genetic linkage, Molecular genetics, Genetic engineering, Genomics, Chromosomal abnormalities, Mendelian inheritance, Genetic markers, Bioinformatics, Functional genomics

#Genetics, #DNA, #GeneTherapy, #CRISPR, #Epigenetics, #GenomeResearch, #GenomicScience, #PopulationGenetics, #GeneEditing, #MolecularBiology, #Bioinformatics, #HereditaryResearch, #GenomicMedicine, #GeneticMarkers, #FunctionalGenomics, #MendelianGenetics, #GeneticDisorders, #GeneticResearch, #ChromosomalStudies, #GeneticVariation

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...